• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Bionano Genomics Inc.

    9/19/25 4:34:20 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BNGO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Bionano Genomics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    09075F404

    (CUSIP Number)


    09/16/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09075F404


    1Names of Reporting Persons

    Mitchell P. Kopin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,415.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,415.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,415.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    09075F404


    1Names of Reporting Persons

    Daniel B. Asher
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,415.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,415.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,415.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    09075F404


    1Names of Reporting Persons

    Intracoastal Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,415.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,415.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,415.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Bionano Genomics, Inc.
    (b)Address of issuer's principal executive offices:

    9540 Towne Centre Drive, Suite 100, San Diego, California 92121
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
    (b)Address or principal business office or, if none, residence:

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
    (c)Citizenship:

    Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    09075F404
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on September 16, 2025 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 18, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 525,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock represent beneficial ownership of approximately 9.9% of the Common Stock, based on (1) 4,755,265 shares of Common Stock outstanding as of September 9, 2025, as reported by the Issuer, plus (2) 525,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 525,000 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1") because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (II) 525,000 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (III) 7,278 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,582,278 shares of Common Stock. (ii) As of the close of business on September 19, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 508,415 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, and all such shares of Common Stock represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 4,755,265 shares of Common Stock outstanding as of September 9, 2025, as reported by the Issuer, plus (2) 4,925,000 shares of Common Stock issued at the closing of the transaction contemplated by the SPA and (3) 508,415 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 16,585 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock, (II) 525,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (III) 7,278 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,057,278 shares of Common Stock.
    (b)Percent of class:

    4.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    508,415

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    508,415

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Mitchell P. Kopin
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin
    Date:09/19/2025
     
    Daniel B. Asher
     
    Signature:/s/ Daniel B. Asher
    Name/Title:Daniel B. Asher
    Date:09/19/2025
     
    Intracoastal Capital LLC
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin, Manager
    Date:09/19/2025
    Exhibit Information

    Exhibit 1 - Joint Filing Agreement

    Get the next $BNGO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNGO

    DatePrice TargetRatingAnalyst
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    9/10/2024Buy → Neutral
    BTIG Research
    1/5/2023$4.00Sector Outperform
    Scotiabank
    12/12/2022$3.50Buy
    BTIG Research
    7/18/2022$12.00Outperform
    Oppenheimer
    More analyst ratings

    $BNGO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Bionano Genomics Inc.

    SCHEDULE 13G - Bionano Genomics, Inc. (0001411690) (Subject)

    9/19/25 4:34:20 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form EFFECT filed by Bionano Genomics Inc.

    EFFECT - Bionano Genomics, Inc. (0001411690) (Filer)

    9/17/25 12:15:20 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 424B4 filed by Bionano Genomics Inc.

    424B4 - Bionano Genomics, Inc. (0001411690) (Filer)

    9/16/25 5:20:01 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering

    SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) ("Bionano" or the "Company") today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company's common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company's common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company's common stock (all the warrants, collectively, the "Series Warrants"), at a combined public offering price of $2.00 per share (or common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants have an e

    9/17/25 5:00:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering

    SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) ("Bionano" or the "Company") today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company's common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company's common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company's common stock (all the warrants, collectively, the "Series Warrants"), at a combined public offering price of $2.00 per share (or common stock equivalent in lieu thereof) and accompanying Series Warrants. The Series Warrants will have an exercise price of $

    9/16/25 9:10:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology

    SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research. According to research, chromoanagenesis refers to a catastrophic genomic event frequently associated with highly complex karyotypes, extensive clonal heterogeneity, treatment resistance, and poor prognosis. It includes events such as chromothripsis, chromoplexy, and chromoanasynthesis, all of which play a significant rol

    9/16/25 7:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bionano Genomics downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral

    11/15/24 7:40:01 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics downgraded by BTIG Research

    BTIG Research downgraded Bionano Genomics from Buy to Neutral

    9/10/24 7:37:53 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on Bionano Genomics with a new price target

    Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00

    1/5/23 7:29:54 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Operating Officer Oldakowski Mark covered exercise/tax liability with 59 shares, decreasing direct ownership by 6% to 915 units (SEC Form 4)

    4/A - Bionano Genomics, Inc. (0001411690) (Issuer)

    9/12/25 5:02:22 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Operating Officer Oldakowski Mark covered exercise/tax liability with 59 shares, decreasing direct ownership by 6% to 915 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    9/12/25 4:49:30 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Medical Officer Chaubey Alka covered exercise/tax liability with 51 shares, decreasing direct ownership by 7% to 662 units (SEC Form 4)

    4 - Bionano Genomics, Inc. (0001411690) (Issuer)

    9/12/25 4:49:08 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Financials

    Live finance-specific insights

    View All

    Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress

    SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the second quarter ended June 30, 2025. "We continued to execute on our new strategy of focusing on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit in the second quarter. These routine users are increasingly leveraging our OGM systems and software and we believe the recent upgrades to our software and compute platforms will drive further utilization. I'm very proud of our team for driving gross margin above 50% this quarter, which combined with our continued efforts to reduce costs, gives

    8/14/25 4:01:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report Second Quarter 2025 Financial Results and Host a Conference Call Webcast on August 14, 2025

    SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Thursday, August 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, August 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/tnombut6/ Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h

    7/31/25 4:05:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

    SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b

    5/7/25 4:01:00 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Leadership Updates

    Live Leadership Updates

    View All

    LeddarTech Appoints Chris Stewart as Chief Financial Officer

    QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial

    11/15/23 12:07:00 AM ET
    $BNGO
    $PRSR
    $TSLA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Blank Checks
    Finance

    Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

    SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe

    8/14/23 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bionano Genomics Appoints Donna Polizio as Its First Ever Global Head of Market Access

    SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has appointed Donna Polizio as its global head of market access, further strengthening its leadership team. The appointment of a global head of market access reflects Bionano's focus on advancing the adoption of optical genome mapping (OGM) and working to meet market needs. Ms. Polizio was most recently the vice president of U.S. managed care and reimbursement at Genomic Health, acquired by Exact Sciences in 2019. In this role, she managed payor contracting and reimbursements that helped drive profitability of Genomic Health prior to its acquisition. Ms. Polizio has also held senior l

    11/10/22 8:00:00 AM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BNGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    2/13/24 5:00:51 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    7/7/23 4:35:55 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Bionano Genomics Inc. (Amendment)

    SC 13G/A - Bionano Genomics, Inc. (0001411690) (Subject)

    1/30/23 4:03:23 PM ET
    $BNGO
    Biotechnology: Laboratory Analytical Instruments
    Industrials